bioRxivCancer BiologyPreprint
Iron and lipocalin-2 modulate cellular responses in the tumor micro-environment of pancreatic ductal adenocarcinoma
V. Pita-Grisanti, A. W. Dangel, K. Gumpper, A. Ludwig, O. Ueltschi, X. M. Mo, M. Pietrzak, A. Webb, R. F. Hwang, M. Traczek, N. Badi, Z. Cruz-Monserrate
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease with poor outcomes. Iron is known to signal cellular responses, and its levels are regulated by lipocalin-2 (LCN2) expression, a PDAC pro-tumorigenic molecule. However, how iron and LCN2 function in PDAC is unclear. Here we demonstrate that iron levels regulate PDAC cell proliferation, invasion, expression of epithelial to mesenchymal tumor markers, and pro-inflammatory cytokines. Iron chelation increased the expression of the LCN2 receptor SLC22A17 in pancreatic stellate cells and the anti-metastatic gene NDRG1 in PDAC cells. Deletion of Lcn2 in mouse tumor cells modulated the expression of genes involved in extracellular matrix deposition and cell migration. Moreover, cellular iron responses were dependent on the Kras mutation status of cells, and LCN2 expression levels. Deletion of Lcn2 expression in PDAC suggests a protective role against metastasis. Thus, iron modulation and LCN2 blockade could serve as potential therapeutic approaches against PDAC.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation
Satoshi Ogawa, Hyemin Song, … Dannielle D. Engle·bioRxiv·Apr 10, 2026
- LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic Cancer
Thalita Bueno Corrêa, Gabriel Lucas da Fonseca, … Daniela S. Daniela Sanchez Bassères·bioRxiv·Sep 29, 2025
- PI5P4Kα Regulates Iron Balance to Promote Metabolic Fitness in Pancreatic Cancer
Gurpreet K. Arora, Ryan M. Loughran, … Brooke M. Emerling·Cell ReportsPeer-reviewed·Aug 29, 2025
- PCSK9 dependent cholesterol acquisition and utilization underlies metastatic organ preference in pancreatic cancer.
Gilles Rademaker, Grace A. Hernandez, … Rushika M. Perera·bioRxiv·Apr 22, 2025
- TNFR2 blockade promotes anti-tumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion
A. Debesset, C. Pilon, … J. L. Cohen·bioRxiv·Jan 22, 2024
- Nischarin agonist rilmenidine shows antimetastatic potential in pancreatic ductal adenocarcinoma
Kristina Živić, Marijana Pavlović, … Jelena Grahovac·bioRxiv·Oct 27, 2025